CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand. 1998

K Saoulli, and S Y Lee, and J L Cannons, and W C Yeh, and A Santana, and M D Goldstein, and N Bangia, and M A DeBenedette, and T W Mak, and Y Choi, and T H Watts
Department of Immunology, and Amgen Institute, University of Toronto, Toronto, Ontario M5S 1A8, Canada.

4-1BB ligand (4-1BBL) is a member of the tumor necrosis factor (TNF) family expressed on activated antigen-presenting cells. Its receptor, 4-1BB, is a member of the TNF receptor family expressed on activated CD4 and CD8 T cells. We have produced a soluble form of 4-1BBL using the baculovirus expression system. When coimmobilized on plastic with anti-CD3, soluble 4-1BBL induces interleukin (IL)-2 production by resting CD28+ or CD28- T cells, indicating that 4-1BBL can function independently of other cell surface molecules, including CD28, in costimulation of resting T cell activation. At low concentrations of anti-CD3, 4-1BBL is inferior to anti-CD28 in T cell activation. However, when 4-1BB ligand is provided together with strong TCR signals, then 4-1BBL and anti-CD28 are equally potent in stimulation of IL-2 production by resting T cells. We find that TNF receptor-associated factor (TRAF)1 or TRAF2 associate with a glutathione S-transferase-4-1BB cytoplasmic domain fusion protein in vitro. In T cells, we find that association of TRAF1 and TRAF2 with 4-1BB requires 4-1BB cross-linking. In support of a functional role for TRAF2 in 4-1BB signaling, we find that resting T cells isolated from TRAF2-deficient mice or from mice expressing a dominant negative form of TRAF2 fail to augment IL-2 production in response to soluble 4-1BBL. Thus 4-1BB, via the TRAF2 molecule, can provide CD28-independent costimulatory signals to resting T cells.

UI MeSH Term Description Entries
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D011506 Proteins Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein. Gene Products, Protein,Gene Proteins,Protein,Protein Gene Products,Proteins, Gene
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D005822 Genetic Vectors DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition. Cloning Vectors,Shuttle Vectors,Vectors, Genetic,Cloning Vector,Genetic Vector,Shuttle Vector,Vector, Cloning,Vector, Genetic,Vector, Shuttle,Vectors, Cloning,Vectors, Shuttle
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000906 Antibodies Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).

Related Publications

K Saoulli, and S Y Lee, and J L Cannons, and W C Yeh, and A Santana, and M D Goldstein, and N Bangia, and M A DeBenedette, and T W Mak, and Y Choi, and T H Watts
February 2003, European journal of immunology,
K Saoulli, and S Y Lee, and J L Cannons, and W C Yeh, and A Santana, and M D Goldstein, and N Bangia, and M A DeBenedette, and T W Mak, and Y Choi, and T H Watts
January 1997, Journal of immunology (Baltimore, Md. : 1950),
K Saoulli, and S Y Lee, and J L Cannons, and W C Yeh, and A Santana, and M D Goldstein, and N Bangia, and M A DeBenedette, and T W Mak, and Y Choi, and T H Watts
June 1999, Journal of immunology (Baltimore, Md. : 1950),
K Saoulli, and S Y Lee, and J L Cannons, and W C Yeh, and A Santana, and M D Goldstein, and N Bangia, and M A DeBenedette, and T W Mak, and Y Choi, and T H Watts
April 1997, Journal of immunology (Baltimore, Md. : 1950),
K Saoulli, and S Y Lee, and J L Cannons, and W C Yeh, and A Santana, and M D Goldstein, and N Bangia, and M A DeBenedette, and T W Mak, and Y Choi, and T H Watts
January 2003, Cytokine & growth factor reviews,
K Saoulli, and S Y Lee, and J L Cannons, and W C Yeh, and A Santana, and M D Goldstein, and N Bangia, and M A DeBenedette, and T W Mak, and Y Choi, and T H Watts
July 2019, Clinical cancer research : an official journal of the American Association for Cancer Research,
K Saoulli, and S Y Lee, and J L Cannons, and W C Yeh, and A Santana, and M D Goldstein, and N Bangia, and M A DeBenedette, and T W Mak, and Y Choi, and T H Watts
February 2008, Cancer immunology, immunotherapy : CII,
K Saoulli, and S Y Lee, and J L Cannons, and W C Yeh, and A Santana, and M D Goldstein, and N Bangia, and M A DeBenedette, and T W Mak, and Y Choi, and T H Watts
July 2001, Journal of immunology (Baltimore, Md. : 1950),
K Saoulli, and S Y Lee, and J L Cannons, and W C Yeh, and A Santana, and M D Goldstein, and N Bangia, and M A DeBenedette, and T W Mak, and Y Choi, and T H Watts
May 2003, Cancer research,
K Saoulli, and S Y Lee, and J L Cannons, and W C Yeh, and A Santana, and M D Goldstein, and N Bangia, and M A DeBenedette, and T W Mak, and Y Choi, and T H Watts
January 2016, PloS one,
Copied contents to your clipboard!